Clinical Trial Update: A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of RAD001 (everolimus) and sunitinib in metastatic renal cell carcinoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Sunitinib (sunitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 1 | Status: COMPLETED